SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma - Cote, Gregory M.; Chawla, Sant P.; Demetri, George; Kasper, Bernd; Jones, Robin L.; Broto, Javier Martin; Wooley, Joseph; Weiss, Mia C.; Tafuto, Salvatore; Badalamenti, Giuseppe; Carrasco, Irene; Peinado, Paloma; et al. (Future oncology, 2025)
Online veröffentlicht: 11. Februar 2025